

Research progress on circadian clock genes in common abdominal malignant tumors (Review)

SHENG-LI YANG¹, QUAN-GUANG REN¹, LU WEN¹, JIAN-LI HU¹ and HENG-YI WANG²

¹Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P.R. China; ²Department of Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China

Received January 30, 2016; Accepted July 3, 2017

DOI: 10.3892/ol.2017.6856

Abstract. The circadian clock refers to the inherent biological rhythm of an organism, which, is accurately regulated by numerous clock genes. Studies in recent years have reported that the abnormal expression of clock genes is ubiquitous in common abdominal malignant tumors, including liver, colorectal, gastric and pancreatic cancer. In addition, the abnormal expression of certain clock genes is closely associated with clinical tumor parameters or patient prognosis. Studies in clock genes may expand the knowledge about the mechanism of occurrence and development of tumors, and may provide a new approach for tumor therapy. The present study summarizes the research progress in this field.

Contents

1. Introduction
2. CLOCK
3. BMAL1
4. Per1, Per2 and Per3
5. Cry1 and Cry2
6. NPAS2
7. CKI ϵ
8. Rev-Erb- α and Rev-Erb- β
9. DEC1 and DEC2
10. Tim
11. Conclusions

Correspondence to: Professor Jian-Li Hu, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, P.R. China
E-mail: jl5199@126.com

Professor Heng-Yi Wang, Department of Surgery, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui 230022, P.R. China
E-mail: gdh00909@sina.com

Key words: circadian clock, abdominal surgery, malignant tumor, cancer

1. Introduction

The earliest finding of a circadian clock was the change in position of plant leaves, which spread during the day and droop at night, corresponding to an oscillation with a 24-h period (1,2). Subsequently, circadian clocks were also identified in the form of clear circadian rhythms in the eclosion of insects (3-6), hibernation of animals (7-9), and body temperature, blood pressure and pulse in humans (10-13). The circadian clock is an inherent rhythm developed by life on the earth's surface during the long-term evolutionary process to adapt to ambient and external environments (particularly, to the sunrise and sunset) (14,15).

Multiple clock genes, including circadian locomotor output cycles kaput (CLOCK), brain and muscle arylhydrocarbon receptor nuclear translocator (ARNT)-like 1 (BMAL1), period (Per)1, Per2, Per3, cryptochrome (Cry)1, Cry2, neuronal Per-Arnt-Sim (PAS) domain protein 2 (NPAS2), casein kinase I ϵ (CKI ϵ), timeless (Tim), nuclear receptor subfamily 1, group D, member 1 (NR1D1, also known as Rev-Erb- α) and differentiated embryo-chondrocyte expressed gene (DEC), accurately regulate the human circadian clock at the molecular level (16-18). These genes constitute two important feedback loops. CLOCK is the core factor of the circadian clock and combines with BMAL1 to form a heterodimer through its basic helix-loop-helix (bHLH)-PAS structural domain. The heterodimer combines with the E-box on the promoter of the Per1-3 and Cry1-2 genes, and activates their transcription. The coding products, the Per1-3 and Cry1-2 proteins, are transported from the cytoplasm to the nucleus, where they directly combine with CLOCK/BMAL1, which inhibits their activities and further blocks the transcription of Per1-3 and Cry1-2. In addition to activating the transcription of Per1-3 and Cry1-2, the CLOCK/BMAL1 heterodimer also activates the transcription of the orphan nuclear receptor Rev-Erb gene (17,19) (Fig. 1). The protein encoded by the Rev-Erb gene can combine with the BMAL1 promoter and block its transcription (17). Since genetic transcription, translation and protein transport from the cytoplasm to the nucleus lasts a certain time, the oscillation of the biological rhythm proceeds with a periodic length of ~24 h via self-induction (18,19). Such a negative feedback cycle of the clock genes forms a precise




Figure 1. Representation of the circadian clock network. CLOCK or NPAS2 combines with BMAL1 to form a core CLOCK/BMAL1 or NPAS2/BMAL1 transcriptional complex, which subsequently activates the transcription of *Per1-3* and *Cry1-2* via E-box elements on their promoters. DEC1 can compete with CLOCK/BMAL1 or NPAS2/BMAL1 heterodimers for E-box binding and therefore inhibit CLOCK/BMAL1-mediated transactivation. The coding products, the *Per1-3* and *Cry1-2* proteins, form a multimeric complex, translocate from the cytoplasm to the nucleus and inhibit CLOCK/BMAL1-mediated transcription. Degradation of *Per1-3* and *Cry1-2* proteins prompts a new circadian cycle whereby CLOCK/BMAL1 transcription is reinitiated. The CLOCK/BMAL1 heterodimer also activates the transcription of the orphan nuclear receptor *Rev-Erb* gene. The protein encoded by the *Rev-Erb* gene can combine with the BMAL1 promoter and block its transcription. Besides transcriptional regulation, post-translational modifications are also involved in the modulation of circadian proteins. CKI ϵ can phosphorylate *Per1-3* and *Cry1-2* proteins, and enable *Per1-3* and *Cry1-2* proteins to be translocated from the cytoplasm to the nucleus. In addition, CKI ϵ -mediated phosphorylation can also destabilize *Per1-3* proteins. Finally, the CLOCK/BMAL1 complex regulates the expression of CCGs, including oncogenes (*c-myc*), tumor-suppressor genes (*P53* and *P21*), genes involved in the regulation of the cell cycle (cyclins A, B1 and D1, and *WEE1* G2 checkpoint kinase) and *VEGF*. These target genes regulated by the biological clock genes are involved in DNA repair, cell proliferation and apoptosis. Therefore, circadian clock disorders may lead to uncontrolled cell growth and malignant transformation. CLOCK, circadian locomotor output cycles kaput; NPAS2, neuronal Per-Arnt-Sim domain-containing protein 2; BMAL1, brain and muscle arylhydrocarbon receptor nuclear translocator-like 1; *Per*, period; *Cry*, cryptochrome; DEC, differentiated embryo-chondrocyte expressed gene; CKI ϵ , casein kinase I ϵ ; CCG, circadian-clock-controlled gene; *VEGF*, vascular endothelial growth factor.

endogenous ‘molecular clock’ in the body. Clock genes output the rhythm signal of a circadian clock through downstream clock controlled genes (CCGs). Thereby, molecular activity within the cell also exhibits a temporal rhythm (18,19).

2. CLOCK

In May 1997, the Takahashi research group of Northwestern University (Evanston, USA) successfully cloned the murine *CLOCK* gene (20). This represented a milestone in the study of the molecular mechanism of circadian clocks in mammals. In 1999, this group reported the cloning of the human *CLOCK* gene, which is located on the long arm of chromosome 4 (4q12) and comprises a protein-coding sequence of 2,538 bp. The *CLOCK* gene belongs to the bHLH-PAS family of transcriptional regulatory factors (21). The containing bHLH domain participates in protein-protein interactions for the formation of protein dimers (21). Two PAS structural domains (PAS-A and PAS-B) mediate the combination of the protein with DNA. Furthermore, the glutamine-rich C-terminus of the *CLOCK* protein also participates in transcriptional activation (21). The *CLOCK* gene is a necessary regulator of the circadian rhythm and serves a central role in the circadian clock system. Homozygote mice with *CLOCK* mutations

develop both circadian clock rhythm and feeding rhythm disorders (22,23).

3. BMAL1

BMAL1, also called *ARNT3*, was identified by Ikeda and Nomura in 1997 (24). *BMAL1* is 32-kb long and its coding product belongs to the bHLH-PAS family (24). A clear circadian rhythm was observed in the expression pattern of *BMAL1* in suprachiasmatic nuclei (SCN) of mice (25). *BMAL1* knockout mice completely lose their circadian rhythm in constant darkness (25). In addition to participating in the regulation of the circadian clock, *BMAL1* is also associated with glucose metabolism (26-28), energy conservation (26-28) and aging (29,30).

4. *Per1*, *Per2* and *Per3*

In 1971, Konopka and Benzer located the *Per* gene in the X chromosome of *Drosophila* when observing the influence of gene mutations on the circadian rhythm (31). The *Per* gene of *Drosophila* has three mutant types: *PerO*, *PerL* and *PerS*. These mutant phenotypes exhibit circadian rhythm disappearance, extension and shortening, respectively. Subsequently, similar

genes to the *Per* gene of *Drosophila* with genotypes *Per1*, *Per2* and *Per3* were also identified in mice and humans (31). The *Per1-3* genes not only participate in the regulation of the circadian clock, but also inhibit the growth and proliferation of tumor cells, and induce apoptosis, thus being considered as potential tumor-suppressor genes (32-36).

5. *Cry1* and *Cry2*

The *Cry* gene was initially discovered in plants (37). It encodes the photoreception molecule of blue light and participates in the circadian rhythm reaction guided by blue light in plants. Although this gene also is present in mammals in the mutant forms *Cry1* and *Cry2*, it is unable to act as a photoreceptor in mammals (38). The mutation of mouse (m)*Cry2* leads to a 1-h extension of free-motion period. However, the *Cry1* mutant manifests the reverse phenotype. The mutant of both m*Cry1* and m*Cry2* manifests circadian rhythm disorders, which indicates that m*Cry1* and m*Cry2* are core elements of the circadian rhythm (38).

6. NPAS2

NPAS2, also known as member of PAS protein 4 (MOP4), is located on the human chromosome 2p11.2-2q13. Similar to *CLOCK*, NPAS2 also belongs to the bHLH-PAS family. NPAS2 exhibits the bHLH structural domain at its N-terminus, and two PAS structural domains (PAS-A and PAS-B) in addition to a nuclear receptor-joining region at its C-terminus (39). NPAS2 can regulate the circadian clock rhythm by forming an NPAS/BMAL1 heterodimer with BMAL1, combining with the target gene promoter E-box, and regulating the expression of the *Per* and *Cry* genes (40). NPAS2 is an essential gene to maintain a normal biological rhythm. Disorders of the circadian rhythm could be caused by mutation or deletion of NPAS2 (40). In addition, NPAS2 also regulates and interferes with oncogenes, tumor-suppressor genes, and genes associated with the cell cycle, cell proliferation and apoptosis (41-43). Furthermore, NPAS2 is important in cell cycle regulation, DNA damage repair response and tumor growth inhibition, and may also act as a tumor-suppressor gene (41-43).

7. CKI ϵ

CKI ϵ was cloned in 1995 (44). Its protein product, CKI ϵ , belongs to the serine/threonine kinase family, has a relative molecular weight of 43.7 kDa and is widely distributed in its monomeric form (44). CKI ϵ can phosphorylate BMAL1, *Per1*, *Per2*, *Per3*, *Cry1* and *Cry2* proteins, thus regulating their activity and stability. In addition, CKI ϵ can regulate clock genes at the post-translational level (45-47).

8. Rev-Erb- α and Rev-Erb- β

Rev-Erb- α (identified in 1989) and Rev-Erb- β (identified in 1994) are members of the nuclear receptor superfamily of ligand-inducible transcription factors (48,49). Both receptors possess a DNA-binding domain with a conservative zinc finger and a ligand-binding domain. The DNA-binding domain contains the sequence coding the nuclear localization

signal. Depending on the circadian rhythm, these domains are expressed in the human supraoptic nuclei, liver and heart (48,49). Rev-Erb- α can inhibit the expression of *CLOCK* (50), *BMAL1* (51) and *NPAS2* (52). The *SCN* of Rev-Erb- α knockout mice do not periodically express *BMAL1* and their active phase is shortened. This indicates that Rev-Erb- α is required for maintaining the accuracy of the circadian clock (53). A previous study indicated that Rev-Erb- α and Rev-Erb- β coordinated to protect against major perturbations in circadian and metabolic physiology (54). The periodic expression of the core circadian clock and the lipid metabolism network were observed to be markedly dysregulated in Rev-Erb- α and Rev-Erb- β knockout mice, which indicates that Rev-Erb- α and Rev-Erb- β are also important components of the circadian clock core mechanism (17,55,56).

9. DEC1 and DEC2

The genes *DEC1* and *DEC2* were identified in 1997 (57) and 2001 (58), respectively. Both transcription factors contain the bHLH structure, but not the PAS domain. The level of homology of *DEC1* and *DEC2* in the bHLH region is 97%, while that in the orange region (a motif of ~35 amino acids located C-terminally of the bHLH domain, providing an additional protein-protein interaction interface) is only 52% (59). In contrast to *DEC1*, the *DEC2* transcription factor is rich in alanine and glycine, which may be one of the main reasons for their functional difference (59,60). *DEC1* is widely expressed in multiple tissues, while the expression of *DEC2* is highly tissue-dependent (59,60). *DEC1* can downregulate and inhibit the activity of *DEC2*. Following combination with E-box functional elements (CACGTG) located on the clock gene promoter, *DEC1* and *DEC2* regulate the circadian clock rhythm through inhibiting the transcriptional activation process mediated by the *CLOCK/BMAL1* heterodimer (61,62). Both transcription factors, particularly *DEC2*, are closely associated with sleep disorders (61). In addition, *DEC1* and *DEC2* also participate in regulating the expression of factors associated with tumor growth and apoptosis, and are linked to tumor occurrence and development (63-66).

10. Tim

In 1994, Sehgal *et al* screened a new mutant influencing the biological rhythm of *Drosophila* in a similar manner than *PerO*. The corresponding wild-type gene of this mutant gene was named *Tim* (67). Since the identification of the *Tim* gene occurred on the 1990s, in-depth studies are still required at present to elucidate its role in the regulation of the human circadian clock (68).

11. Conclusions

In recent years, due to the accelerated pace of life and an increased pressure for competition, a large number of people stay awake until late, lose sleep and miss meals, causing a circadian clock disorder and an increase in circadian clock disorder-related diseases (69-71). Epidemiologic studies revealed that circadian rhythm disorders (mainly caused by the influence of light) are correlated with breast, ovarian and

Table I. Expression of clock genes in liver, colorectal, gastric and pancreatic cancer.

Author, year	Cancer type	Country	Carcinoma/peritumoral tissue cases, n	Detection method	Clock gene expression										Tim (Refs.)
					CLOCK	BMAL1	Per1	Per2	Per3	Cry1	Cry2	CKIε			
Lin <i>et al</i> , 2008	Liver	Taiwan	46/46	RT-qPCR and IHC	NS	NS	↓	↓	↓	NS	↓	↓	NS	↓	(82)
Yang <i>et al</i> , 2014	Liver	China	30/30	RT-qPCR	NS	NS	↓	↓	↓	NS	↓	↓	NS	ND	(83)
Krugluger, <i>et al</i> 2007	Colorectal	Austria	30/30	RT-qPCR	NS	ND	↓	NS	ND	ND	ND	ND	ND	ND	(84)
Wang <i>et al</i> , 2011	Colorectal	China	38/38	RT-qPCR and IHC	ND	ND	↓	↓	↓	ND	ND	ND	ND	ND	(85)
Mazzocchi <i>et al</i> , 2011	Colorectal	Italy	19/19	RT-qPCR	NS	ND	↓	↓	↓	NS	↓	↓	NS	↑	(86)
Oshima <i>et al</i> , 2011	Colorectal	Japan	202/202	RT-qPCR	↑	NS	↓	NS	↓	NS	NS	NS	↑	ND	(87)
Wang <i>et al</i> , 2012	Colorectal	China	203/203	RT-qPCR and IHC	ND	ND	ND	ND	↓	ND	ND	ND	ND	ND	(88)
Karantanos <i>et al</i> , 2013	Colorectal	China	30/30	RT-qPCR and IF	↑	ND	ND	ND	ND	ND	ND	ND	ND	ND	(89)
Wang <i>et al</i> , 2013	Colorectal	China	168/10	RT-qPCR and IHC	ND	ND	ND	ND	ND	↑	ND	ND	ND	ND	(90)
Yu <i>et al</i> , 2013	Colorectal	Greece	42/42	RT-qPCR	↑	↑	↓	NS	↓	ND	ND	ND	ND	ND	(91)
Wang <i>et al</i> , 2015	Colorectal	China	203/203	RT-qPCR and IHC	ND	ND	↓	ND	ND	ND	ND	ND	ND	ND	(92)
Zhao <i>et al</i> , 2014	Gastric	China	246/45	IHC	ND	ND	↓	ND	↓	ND	ND	ND	ND	ND	(93)
Hu <i>et al</i> , 2014	Gastric	Taiwan	29/29	RT-qPCR and IHC	NS	NS	NS	↑	NS	NS	NS	NS	NS	NS	(94)
Relles <i>et al</i> , 2013	Pancreatic	USA	65/50	RT-qPCR	NS	NS	↓	↓	↓	NS	↓	↓	↓	NS	(95)

CLOCK, circadian locomotor output cycles kaput; BMAL1, brain and muscle arylhydrocarbon receptor nuclear translocator-like 1; Per, period; Cry, cryptochrome; CKIε, casein kinase Iε; CCG, circadian-clock-controlled gene; Tim, timeless; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; IHC, immunohistochemistry; IF, immunofluorescence; NS, no significant difference between expression in carcinoma and para-carcinoma tissues; ↓, decreased expression in carcinoma tissue; ↑, increased expression in carcinoma tissue; ND, not detected.

Table II. Association between expression of clock genes and clinical parameters of liver, colorectal, gastric and pancreatic cancer.

Author, year	Cancer type	Country	Association	(Refs.)
Lin <i>et al.</i> , 2008	Liver	Taiwan	Per2 and Per3 were correlated with the size of liver cancer; Tim was correlated with the pathological grade of liver cancer	(82)
Yang <i>et al.</i> , 2014	Liver	China	Association of clock genes with clinical parameters was not analyzed	(83)
Krugluger <i>et al.</i> , 2007	Colorectal	Austria	Per1 expression in poorly differentiated tumors was significantly decreased, particularly in female patients	(84)
Wang <i>et al.</i> , 2011	Colorectal	China	Per2 expression was correlated with the degree of tumor differentiation, TNM stage and depth of infiltration	(85)
Mazzocchi <i>et al.</i> , 2011	Colorectal	Italy	Per1 and Per3 were correlated with patients' survival time; Tim was correlated with TNM stage	(86)
Oshima <i>et al.</i> , 2011	Colorectal	Japan	High expression of BMAL1 and low expression of Per1 were correlated with liver metastasis; patients with high Per2 expression had a better prognosis	(87)
Wang <i>et al.</i> , 2012	Colorectal	China	Per3 was correlated with tumor differentiation, degree of differentiation and TNM stage; Per3-negative patients exhibited a higher mortality and shorter survival time	(88)
Karantanos <i>et al.</i> , 2013	Colorectal	China	High CLOCK expression was positively correlated with poor tumor differentiation, advanced stage and lymphatic metastasis	(89)
Wang <i>et al.</i> , 2013	Colorectal	China	High Cry1 expression was correlated with lymphatic metastasis, TNM stage and poor prognosis	(90)
Yu <i>et al.</i> , 2013	Colorectal	Greece	No association was observed between CLOCK, BMAL1 or Per1-3 and clinical parameters of colorectal cancer	(91)
Wang <i>et al.</i> , 2015	Colorectal	China	The expression of Per1 was significantly associated with distant metastasis, but not with patients' prognosis	(92)
Zhao <i>et al.</i> , 2014	Gastric	China	Per1 and Per2 were correlated with the clinical stage of gastric cancer and depth of infiltration; Per1 was also correlated with lymphatic metastasis and degree of pathological differentiation; patients with high Per2 expression had a better prognosis	(93)
Hu <i>et al.</i> , 2014	Gastric	Taiwan	High Cry1 expression was positively correlated with advanced gastric cancer	(94)
Relles <i>et al.</i> , 2013	Pancreatic	USA	Low expression of clock genes was associated with short survival time	(95)

Per, period; TNM, tumor-node-metastasis; Tim, timeless; BMAL1, brain and muscle arylhydrocarbon receptor nuclear translocator-like 1; CLOCK, circadian locomotor output cycles kaput; Cry, cryptochrome.

prostate cancer. Working on night or rotating shifts is linked to a greatly increased risk for women to develop breast and ovarian cancer, and for men to develop prostate cancer (69-71). Clock genes contribute to the occurrence and development of tumors by regulating and interfering with oncogenes (c-myc), tumor-suppressor genes (P53 and P21), genes involved in the regulation of the cell cycle (cyclins A, B1 and D1, and WEE1 G2 checkpoint kinase) and vascular endothelial growth factor, as well as affecting the internal secretion pathway (72-81) (Fig. 1). These target genes regulated by the biological clock genes are involved in DNA damage repair, cell proliferation and apoptosis. Thus, biological clock disorders are likely to lead to uncontrolled cell growth and malignant transformation (73).

Although the exact association between clock genes and common abdominal malignant tumors, including liver cancer (82,83), colorectal cancer (84-92), gastric cancer (93,94) and pancreatic cancer (95), is not clear yet, it has been demonstrated that an abnormal expression of clock genes is ubiquitous in these tumors. Abnormal expression of the CLOCK gene may be one of the important reasons for occurrence and development of these tumors. The relevant articles are summarized in Tables I and II.

As shown in these tables, only a few articles focus on clock genes in abdominal tumors. The majority of them are single-center and small-sample studies, mainly focusing on colon cancer and genes such as CLOCK, BMAL1, Per1, Per2, Per3, Cry1, Cry2, CKI ϵ and Tim, whereas only a few studies focus on NPAS2, Rev-Erb and DEC (83-91,93-95). Low expression of Per1 and Per3 in liver, colon and pancreatic cancer has been observed, and Per1 and Per3 are closely associated with prognosis (83-91,93-95) (Tables I and II).

Currently, the reason and mechanism of low expression of clock genes in abdominal tumors are not clear. Preliminary studies indicate that, in liver cancer, hypoxia, hypoxia inducible factor (HIF)-1 α , HIF-2 α and hepatitis B virus X protein (HBx) can disrupt the expression of circadian clock genes (83,96). Besides HBx, hepatitis C virus can also modulate the hepatic clock gene machinery (97). Therefore, it can be hypothesized that the tumor microenvironment and virus infections may contribute to circadian clock disorders in hepatocellular carcinoma cells (83,96).

The new interdisciplinary generated by the integration of chronobiology and onco-molecular biology is expected to expand the knowledge about tumor occurrence and development, and may provide a new approach for tumor therapy (98-102). Tumor chronotherapy, which is the selection of the optimum treatment time to achieve the maximum curative effect and the minimum toxic and side effects based on the rhythm characteristics of tumor growth, has achieved satisfactory results in clinical practice (98-102). However, the association between clock genes and tumors remains to be fully understood. The circadian clock system of *Drosophila* is well understood, but this knowledge cannot be completely transferred to the human circadian clock, as this is more complex than that of *Drosophila* and large individual differences exist. Numerous factors in the natural and social environments that can influence the human circadian clock and the formation of tumors have not yet been fully elucidated. However, future findings in this field will lead to an

increased knowledge in the disciplines of tumor and circadian clock research.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81702885), the Fundamental Research Funds for the Central Universities: the Independent Innovation Fund of Huazhong University of Science and Technology (HUST: 2016YXMS241), Chinese Foundation for Hepatitis Prevention and Control "Tian Qing" Liver Research Fund and China Postdoctoral Science Foundation funded project (2017M613001).

References

1. Montenegro-Montero A, Canessa P and Larrondo LF: Around the fungal clock: Recent advances in the molecular study of circadian clocks in neurospora and other fungi. *Adv Genet* 92: 107-184, 2015.
2. Endo M: Tissue-specific circadian clocks in plants. *Curr Opin Plant Biol* 29: 44-49, 2016.
3. Di Cara F and King-Jones K: How clocks and hormones act in concert to control the timing of insect development. *Curr Top Dev Biol* 105: 1-36, 2013.
4. Tomioka K: Chronobiology of crickets: A review. *Zoolog Sci* 31: 624-632, 2014.
5. Numata H, Miyazaki Y and Ikeno T: Common features in diverse insect clocks. *Zoological Lett* 1: 10, 2015.
6. Uryu O, Ameku T and Niwa R: Recent progress in understanding the role of ecdysteroids in adult insects: Germline development and circadian clock in the fruit fly *Drosophila melanogaster*. *Zoological Lett* 1: 32, 2015.
7. Heller HC and Ruby NF: Sleep and circadian rhythms in mammalian torpor. *Annu Rev Physiol* 66: 275-289, 2004.
8. Ruby NF: Hibernation: When good clocks go cold. *J Biol Rhythms* 18: 275-286, 2003.
9. Coomans CP, Ramkisoensing A and Meijer JH: The suprachiasmatic nuclei as a seasonal clock. *Front Neuroendocrinol* 37: 29-42, 2015.
10. Leslie M: Circadian rhythms. Sleep study suggests triggers for diabetes and obesity. *Science* 336: 143, 2012.
11. Bass J: Circadian topology of metabolism. *Nature* 491: 348-356, 2012.
12. Richards J, Diaz AN and Gumz ML: Clock genes in hypertension: Novel insights from rodent models. *Blood Press Monit* 19: 249-254, 2014.
13. McLoughlin SC, Haines P and FitzGerald GA: Clocks and cardiovascular function. *Methods Enzymol* 552: 211-228, 2015.
14. Robinson I and Reddy AB: Molecular mechanisms of the circadian clockwork in mammals. *FEBS Lett* 588: 2477-2483, 2014.
15. Li S and Zhang L: Circadian control of global transcription. *Biomed Res Int* 2015: 187809, 2015.
16. Huang N, Chelliah Y, Shan Y, Taylor CA, Yoo SH, Partch C, Green CB, Zhang H and Takahashi JS: Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. *Science* 337: 189-194, 2012.
17. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, DiTacchio L, Atkins AR, Glass CK, *et al*: Regulation of circadian behaviour and metabolism by REV-ERB- α and REV-ERB- β . *Nature* 485: 123-127, 2012.
18. Bersten DC, Sullivan AE, Peet DJ and Whitelaw ML: bHLH-PAS proteins in cancer. *Nat Rev Cancer* 13: 827-841, 2013.
19. Mazzocchi G, Paziienza V and Vinciguerra M: Clock genes and clock-controlled genes in the regulation of metabolic rhythms. *Chronobiol Int* 29: 227-251, 2012.
20. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, Steeves TD, Vitaterna MH, Kornhauser JM, Lowrey PL, *et al*: Positional cloning of the mouse circadian clock gene. *Cell* 89: 641-653, 1997.
21. Steeves TD, King DP, Zhao Y, Sangoram AM, Du F, Bowcock AM, Moore RY and Takahashi JS: Molecular cloning and characterization of the human CLOCK gene: Expression in the suprachiasmatic nuclei. *Genomics* 57: 189-200, 1999.
22. Naylor E, Bergmann BM, Krauski K, Zee PC, Takahashi JS, Vitaterna MH and Turek FW: The circadian clock mutation alters sleep homeostasis in the mouse. *J Neurosci* 20: 8138-8143, 2000.

23. Lee J, Lee S, Chung S, Park N, Son GH, An H, Jang J, Chang DJ, Suh YG and Kim K: Identification of a novel circadian clock modulator controlling BMAL1 expression through a ROR/REV-ERB-response element-dependent mechanism. *Biochem Biophys Res Commun* 469: 580-586, 2016.
24. Ikeda M and Nomura M: cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage. *Biochem Biophys Res Commun* 233: 258-264, 1997.
25. Bunger MK, Wilsbacher LD, Moran SM, Clendenen C, Radcliffe LA, Hogenesch JB, Simon MC, Takahashi JS and Bradfield CA: Mop3 is an essential component of the master circadian pacemaker in mammals. *Cell* 103: 1009-1017, 2000.
26. Young ME, Brewer RA, Pelicciari-Garcia RA, Collins HE, He L, Birky TL, Peden BW, Thompson EG, Ammons BJ, Bray MS, et al: Cardiomyocyte-specific BMAL1 plays critical roles in metabolism, signaling, and maintenance of contractile function of the heart. *J Biol Rhythms* 29: 257-276, 2014.
27. Kennaway DJ, Varcoe TJ, Voultziou A and Boden MJ: Global loss of bmal1 expression alters adipose tissue hormones, gene expression and glucose metabolism. *PLoS One* 8: e65255, 2013.
28. Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB and Fitzgerald GA: BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. *PLoS Biol* 2: e377, 2004.
29. Khapre RV, Kondratova AA, Patel S, Dubrovsky Y, Wrobel M, Antoch MP and Kondratov RV: BMAL1-dependent regulation of the mTOR signaling pathway delays aging. *Aging (Albany NY)* 6: 48-57, 2014.
30. Ali AA, Schwarz-Herzke B, Stahr A, Prozorovski T, Aktas O and von Gall C: Premature aging of the hippocampal neurogenic niche in adult Bmal1-deficient mice. *Aging (Albany NY)* 7: 435-449, 2015.
31. Konopka RJ and Benzer S: Clock mutants of *Drosophila melanogaster*. *Proc Natl Acad Sci USA* 68: 2112-2116, 1971.
32. Lengyel Z, Lovig C, Kommedal S, Keszhelyi R, Szekeres G, Battyáni Z, Csernus V and Nagy AD: Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors. *Tumour Biol* 34: 811-819, 2013.
33. Zhao N, Yang K, Yang G, Chen D, Tang H, Zhao D and Zhao C: Aberrant expression of clock gene period1 and its correlations with the growth, proliferation and metastasis of buccal squamous cell carcinoma. *PLoS One* 8: e55894, 2013.
34. Hsu CM, Lin PM, Lai CC, Lin HC, Lin SF and Yang MY: PER1 and CLOCK: Potential circulating biomarkers for head and neck squamous cell carcinoma. *Head Neck* 36: 1018-1026, 2014.
35. Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenführer J, Oster H and Hengstler JG: Loss of circadian clock gene expression is associated with tumor progression in breast cancer. *Cell Cycle* 13: 3282-3291, 2014.
36. Liu B, Xu K, Jiang Y and Li X: Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. *Int J Clin Exp Pathol* 7: 7863-7871, 2014.
37. Larkin JC and Woolford JL Jr: Molecular cloning and analysis of the CRY1 gene: A yeast ribosomal protein gene. *Nucleic Acids Res* 11: 403-420, 1983.
38. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, Maywood ES, Hastings MH and Reppert SM: mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. *Cell* 98: 193-205, 1999.
39. Zhou YD, Barnard M, Tian H, Li X, Ring HZ, Francke U, Shelton J, Richardson J, Russell DW and McKnight SL: Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. *Proc Natl Acad Sci USA* 94: 713-718, 1997.
40. McNamara P, Seo SB, Rudic RD, Sehgal A, Chakravarti D and Fitzgerald GA: Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: A humoral mechanism to reset a peripheral clock. *Cell* 105: 877-889, 2001.
41. Yuan P, Wang S, Zhou F, Wan S, Yang Y, Huang X, Zhang Z, Zhu Y, Zhang H and Xing J: Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients. *Cancer Sci* 105: 825-832, 2014.
42. Xue X, Liu F, Han Y, Li P, Yuan B, Wang X, Chen Y, Kuang Y, Zhi Q and Zhao H: Silencing NPAS2 promotes cell growth and invasion in DLD-1 cells and correlated with poor prognosis of colorectal cancer. *Biochem Biophys Res Commun* 450: 1058-1062, 2014.
43. Rana S, Shahid A, Ullah H and Mahmood S: Lack of association of the NPAS2 gene Ala394Thr polymorphism (rs2305160:G>A) with risk of chronic lymphocytic leukemia. *Asian Pac J Cancer Prev* 15: 7169-7174, 2014.
44. Fish KJ, Cegielska A, Getman ME, Landes GM and Virshup DM: Isolation and characterization of human casein kinase I epsilon (CKI), a novel member of the CKI gene family. *J Biol Chem* 270: 14875-14883, 1995.
45. Camacho F, Cilio M, Guo Y, Virshup DM, Patel K, Khorkova O, Styren S, Morse B, Yao Z and Keesler GA: Human casein kinase I delta phosphorylation of human circadian clock proteins period 1 and 2. *FEBS Lett* 489: 159-165, 2001.
46. Tsuchiya Y, Akashi M, Matsuda M, Goto K, Miyata Y, Node K and Nishida E: Involvement of the protein kinase CK2 in the regulation of mammalian circadian rhythms. *Sci Signal* 2: ra26, 2009.
47. Lee H, Chen R, Lee Y, Yoo S and Lee C: Essential roles of CKI delta and CKI epsilon in the mammalian circadian clock. *Proc Natl Acad Sci USA* 106: 21359-21364, 2009.
48. Bonnelye E, Vanacker JM, Desbiens X, Begue A, Stehelin D and Laudet V: Rev-erb beta, a new member of the nuclear receptor superfamily, is expressed in the nervous system during chicken development. *Cell Growth Differ* 5: 1357-1365, 1994.
49. Lazar MA, Hodin RA, Darling DS and Chin WW: A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbA alpha transcriptional unit. *Mol Cell Biol* 9: 1128-1136, 1989.
50. Crumbley C and Burris TP: Direct regulation of CLOCK expression by REV-ERB. *PLoS One* 6: e17290, 2011.
51. Dardente H, Fustin JM and Hazlerigg DG: Transcriptional feedback loops in the ovine circadian clock. *Comp Biochem Physiol A Mol Integr Physiol* 153: 391-398, 2009.
52. Crumbley C, Wang Y, Kojetin DJ and Burris TP: Characterization of the core mammalian clock component, NPAS2, as a REV-ERB alpha/ROR alpha target gene. *J Biol Chem* 285: 35386-35392, 2010.
53. Takeda Y, Kang HS, Angers M and Jetten AM: Retinoic acid-related orphan receptor gamma directly regulates neuronal PAS domain protein 2 transcription in vivo. *Nucleic Acids Res* 39: 4769-4782, 2011.
54. Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J and Lazar MA: Rev-erb alpha and Rev-erb beta coordinately protect the circadian clock and normal metabolic function. *Genes Dev* 26: 657-667, 2012.
55. Mazzocchi G, Cai Y, Liu S, Francavilla M, Giuliani F, Piepoli A, Paziienza V, Vinciguerra M, Yamamoto T and Takumi T: REV-ERB alpha and the clock gene machinery in mouse peripheral tissues: A possible role as a synchronizing hinge. *J Biol Regul Homeost Agents* 26: 265-276, 2012.
56. Bhargava A, Herzel H and Ananthasubramanian B: Mining for novel candidate clock genes in the circadian regulatory network. *BMC Syst Biol* 9: 78, 2015.
57. Shen M, Kawamoto T, Yan W, Nakamasu K, Tamagami M, Koyano Y, Noshiro M and Kato Y: Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. *Biochem Biophys Res Commun* 236: 294-298, 1997.
58. Fujimoto K, Shen M, Noshiro M, Matsubara K, Shingu S, Honda K, Yoshida E, Suardita K, Matsuda Y and Kato Y: Molecular cloning and characterization of DEC2, a new member of basic helix-loop-helix proteins. *Biochem Biophys Res Commun* 280: 164-171, 2001.
59. Noshiro M, Furukawa M, Honma S, Kawamoto T, Hamada T, Honma K and Kato Y: Tissue-specific disruption of rhythmic expression of Dec1 and Dec2 in clock mutant mice. *J Biol Rhythms* 20: 404-418, 2005.
60. Wu T, Ni Y, Zhuge F, Sun L, Xu B, Kato H and Fu Z: Significant dissociation of expression patterns of the basic helix-loop-helix transcription factors Dec1 and Dec2 in rat kidney. *J Exp Biol* 214: 1257-1263, 2011.
61. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, Kato Y and Honma K: Dec1 and Dec2 are regulators of the mammalian molecular clock. *Nature* 419: 841-844, 2002.
62. Li Y, Xie M, Song X, Gragen S, Sachdeva K, Wan Y and Yan B: DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter. *J Biol Chem* 278: 16899-16907, 2003.
63. Seino H, Wu Y, Morohashi S, Kawamoto T, Fujimoto K, Kato Y, Takai Y and Kijima H: Basic helix-loop-helix transcription factor DEC1 regulates the cisplatin-induced apoptotic pathway of human esophageal cancer cells. *Biomed Res* 36: 89-96, 2015.

64. Jinhua H, Zhao M, Wei S, Haitao Y, Yuwen W, Lili W, Wei L and Jian Y: Down regulation of differentiated embryo-chondrocyte expressed gene 1 is related to the decrease of osteogenic capacity. *Curr Drug Targets* 15: 432-441, 2014.
65. You J, Lin L, Liu Q, Zhu T, Xia K and Su T: The correlation between the expression of differentiated embryo-chondrocyte expressed gene 1 and oral squamous cell carcinoma. *Eur J Med Res* 19: 21, 2014.
66. Bi H, Li S, Qu X, Wang M, Bai X, Xu Z, Ao X, Jia Z, Jiang X, Yang Y and Wu H: DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase. *Cell Death Dis* 6: e1891, 2015.
67. Sehgal A, Price JL, Man B and Young MW: Loss of circadian behavioral rhythms and per RNA oscillations in the *Drosophila* mutant timeless. *Science* 263: 1603-1606, 1994.
68. Mazzoccoli G, Laukkanen MO, Vinciguerra M, Colangelo T and Colantuoni V: A timeless link between circadian patterns and disease. *Trends Mol Med* 22: 68-81, 2016.
69. Parent MÉ, El-Zein M, Rousseau MC, Pintos J and Siemiatycki J: Night work and the risk of cancer among men. *Am J Epidemiol* 176: 751-759, 2012.
70. Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA and Rossing MA: Nightshift work and risk of ovarian cancer. *Occup Environ Med* 70: 231-237, 2013.
71. Ijaz S, Verbeek J, Seidler A, Lindbohm ML, Ojajarvi A, Orsini N, Costa G and Neuvonen K: Night-shift work and breast cancer—a systematic review and meta-analysis. *Scand J Work Environ Health* 39: 431-447, 2013.
72. Zhao L, Isayama K, Chen H, Yamauchi N, Shigeoyoshi Y, Hashimoto S and Hattori MA: The nuclear receptor REV-ERB α represses the transcription of growth/differentiation factor 10 and 15 genes in rat endometrium stromal cells. *Physiol Rep* 4: pii:e12663, 2016.
73. Canaple L, Kakizawa T and Laudet V: The days and nights of cancer cells. *Cancer Res* 63: 7545-7552, 2003.
74. Schibler U: The daily timing of gene expression and physiology in mammals. *Dialogues Clin Neurosci* 9: 257-272, 2007.
75. Kornmann B, Schaad O, Bujard H, Takahashi JS and Schibler U: System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. *PLoS Biol* 5: e34, 2007.
76. Walker JR and Hogenesch JB: RNA profiling in circadian biology. *Methods Enzymol* 393: 366-376, 2005.
77. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH and Weitz CJ: Extensive and divergent circadian gene expression in liver and heart. *Nature* 417: 78-83, 2002.
78. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS and Hogenesch JB: Coordinated transcription of key pathways in the mouse by the circadian clock. *Cell* 109: 307-320, 2002.
79. McCarthy JJ, Andrews JL, McDearmon EL, Campbell KS, Barber BK, Miller BH, Walker JR, Hogenesch JB, Takahashi JS and Esser KA: Identification of the circadian transcriptome in adult mouse skeletal muscle. *Physiol Genomics* 31: 86-95, 2007.
80. Kornmann B, Preitner N, Rifat D, Fleury-Olela F and Schibler U: Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs. *Nucleic Acids Res* 29: E51-E61, 2001.
81. Duffield GE, Best JD, Meurers BH, Bittner A, Loros JJ and Dunlap JC: Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells. *Curr Biol* 12: 551-557, 2002.
82. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW and Chang JG: Disturbance of circadian gene expression in hepatocellular carcinoma. *Mol Carcinog* 47: 925-933, 2008.
83. Yang SL, Yu C, Jiang JX, Liu LP, Fang X and Wu C: Hepatitis B virus X protein disrupts the balance of the expression of circadian rhythm genes in hepatocellular carcinoma. *Oncol Lett* 8: 2715-2720, 2014.
84. Krugluger W, Brandstaetter A, Kállay E, Schueller J, Krexner E, Kriwanek S, Bonner E and Cross HS: Regulation of genes of the circadian clock in human colon cancer: Reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. *Cancer Res* 67: 7917-7922, 2007.
85. Wang Y, Hua L, Lu C and Chen Z: Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. *World J Surg Oncol* 9: 166, 2011.
86. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A and Piepoli A: Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. *Chronobiol Int* 28: 841-851, 2011.
87. Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, Numata K, Shiozawa M, Rino Y, Tanaka K, *et al*: Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. *Oncol Rep* 25: 1439-1446, 2011.
88. Wang X, Yan D, Teng M, Fan J, Zhou C, Li D, Qiu G, Sun X, Li T, Xing T, *et al*: Reduced expression of PER3 is associated with incidence and development of colon cancer. *Ann Surg Oncol* 19: 3081-3088, 2012.
89. Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Lymberi M and Pektasides D: Expression of clock genes in patients with colorectal cancer. *Int J Biol Markers* 28: 280-285, 2013.
90. Wang L, Chen B, Wang Y, Sun N, Lu C, Qian R and Hua L: hClock gene expression in human colorectal carcinoma. *Mol Med Rep* 8: 1017-1022, 2013.
91. Yu H, Meng X, Wu J, Pan C, Ying X, Zhou Y, Liu R and Huang W: Cryptochrome 1 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer. *PLoS One* 8: e61679, 2013.
92. Wang Y, Xing T, Huang L, Song G, Sun X, Zhong L, Fan J, Yan D, Zhou C, Cui F, *et al*: Period 1 and estrogen receptor-beta are downregulated in Chinese colon cancers. *Int J Clin Exp Pathol* 8: 8178-8188, 2015.
93. Zhao H, Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu XY, Han J, Liu KY, Liao JW, Xu RH and Zou QF: Prognostic relevance of period1 (Per1) and period2 (Per2) expression in human gastric cancer. *Int J Clin Exp Pathol* 7: 619-630, 2014.
94. Hu ML, Yeh KT, Lin PM, Hsu CM, Hsiao HH, Liu YC, Lin HY, Lin SF and Yang MY: Deregulated expression of circadian clock genes in gastric cancer. *BMC Gastroenterol* 14: 67, 2014.
95. Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ and Arafat HA: Circadian gene expression and clinicopathologic correlates in pancreatic cancer. *J Gastrointest Surg* 17: 443-450, 2013.
96. Yu C, Yang SL, Fang X, Jiang JX, Sun CY and Huang T: Hypoxia disrupts the expression levels of circadian rhythm genes in hepatocellular carcinoma. *Mol Med Rep* 11: 4002-4008, 2015.
97. Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, Oben J, Greco A, Williams R, Andriulli A, Vinciguerra M and Pazienza V: Mutual antagonism between circadian protein period 2 and hepatitis C virus replication in hepatocytes. *PLoS One* 8: e60527, 2013.
98. Kondratov R: Circadian clock and cancer therapy: An unexpected journey. *Ann Med* 46: 189-190, 2014.
99. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D and Lévi FA: The circadian timing system in clinical oncology. *Ann Med* 46: 191-207, 2014.
100. Akgun Z, Saglam S, Yucler S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A and Kaytan-Saglam E: Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: A phase II brunch regimen study. *Cancer Chemother Pharmacol* 74: 751-756, 2014.
101. Zarogoulidis P, Darwiche K, Huang H, Spyrtatos D, Yarmus L, Li Q, Kakolyris S, Syrigos K and Zarogoulidis K: Time recall; future concept of chronomodulating chemotherapy for cancer. *Curr Pharm Biotechnol* 14: 632-642, 2013.
102. Chen D, Cheng J, Yang K, Ma Y and Yang F: Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Onco Targets Ther* 6: 1507-1514, 2013.